射血分数降低慢性心衰患者实施沙库巴曲缬沙坦治疗的效果分析  

Effect analysis of sacubitril and valsartan in the treatment of patients with chronic heart failure with reduced ejection fraction

作　　者：周雪峰[1] ZHOU Xue-feng(Department of Cardiovascular Medicine,Hui'an County Hospital,Quanzhou 362100,China)

机构地区：[1]福建惠安县医院心血管内科,362100

出　　处：《中国现代药物应用》2024年第5期75-78,共4页Chinese Journal of Modern Drug Application

摘　　要：目的 评价射血分数降低慢性心力衰竭(心衰)患者应用沙库巴曲缬沙坦治疗的临床效果。方法 选择70例射血分数降低慢性心衰患者,按随机数字表法分为对照组和观察组,各35例。对照组患者采取常规西医对症支持治疗,观察组患者在对照组基础上配合沙库巴曲缬沙坦治疗。比较两组患者的临床疗效、不良反应发生情况及治疗前后心功能指标[左室射血分数(LVEF)、左室收缩末期内径(LVESD)、左室舒张末期内径(LVEDD)]、炎症因子[肿瘤坏死因子-α(TNF-α)、核因子-κB(NF-κB)]水平。结果 观察组总有效率94.29%高于对照组的74.29%(P<0.05)。观察组与对照组不良反应发生率接近(P>0.05)。治疗前,两组患者LVEF、LVESD、LVEDD接近(P>0.05);治疗后,两组LVEF、LVESD、LVEDD较治疗前改善,观察组患者LVESD(38.65±3.05)mm、LVEDD(50.22±5.02)mm低于对照组的(44.08±3.10)、(56.22±5.30)mm, LVEF(46.46±4.02)%高于对照组的(40.60±3.50)%(P<0.05)。治疗前,两组患者TNF-α、NF-κB水平接近(P>0.05);治疗后,两组患者TNF-α、NF-κB较治疗前改善,观察组患者TNF-α(10.20±2.02)ng/L、NF-κB(24.28±2.26)pg/ml低于对照组的(12.95±2.20)ng/L、(30.15±2.70)pg/ml(P<0.05)。结论 对射血分数降低慢性心衰患者进行沙库巴曲缬沙坦治疗后效果明显,可促进患者心功能与炎症因子水平改善,且用药安全性高。Objective To evaluate the clinical effect of sacubitril and valsartan in the treatment of patients with chronic heart failure with reduced ejection fraction.Methods 70 patients with chronic heart failure with reduced ejection fraction were divided into a control group and an observation group according to randomized number table method,with 35 cases in each group.The control group was treated with routine western medicine symptomatic support,and the observation group was treated with sacubitril and valsartan on the basis of the control group.Patients in both groups were compared in terms of clinical efficacy,adverse reactions,cardiac function indicators[left ventricular ejection fraction(LVEF),left ventricular end-systolic diameter(LVESD),left ventricular end-diastolic diameter(LVEDD)],inflammatory factors[tumor necrosis factor-α(TNF-α),nuclear factor-κB(NF-κB)]before and after treatment.Results The total effective rate of the observation group was 94.29%,which was higher than 74.29%of the control group(P<0.05).The incidence of adverse reactions in the observation group and the control group was similar(P>0.05).Before treatment,LVEF,LVESD and LVEDD were similar in the two groups(P>0.05).After treatment,LVEF,LVESD and LVEDD in both groups were improved compared with those before treatment;the observation group had LVESD of(38.65±3.05)mm and LVEDD of(50.22±5.02)mm,which were lower than(44.08±3.10)and(56.22±5.30)mm in the control group;LVEF of(46.46±4.02)%in the observation group was higher than(40.60±3.50)%in the control group(P<0.05).Before treatment,the levels of TNF-αand NF-κB were similar in the two groups(P>0.05).After treatment,TNF-α,NF-κB in both groups were improved compared with those before treatment;the observation group had TNF-αof(10.20±2.02)ng/L and NF-κB of(24.28±2.26)pg/ml,which were lower than(12.95±2.20)ng/L and(30.15±2.70)pg/ml in the control group(P<0.05).Conclusion Sacubitril and valsartan has definite effect on patients with chronic heart failure with reduced ejection fract

关 键 词：射血分数降低 慢性心力衰竭 沙库巴曲缬沙坦 心功能 

分 类 号：R541.6[医药卫生—心血管疾病]